Drug Profile
Research programme: ovarian cancer therapeutics and diagnostics - Lanier Biotherapeutics/RayBiotech
Latest Information Update: 07 Oct 2021
Price :
$50
*
At a glance
- Originator Abeome Corporation; RayBiotech
- Developer Lanier Biotherapeutics
- Class Antibodies; Antibody diagnostics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 05 Oct 2021 Biophtha has merged with Abeome Corporation to form Lanier Biotherapeutics
- 16 Jul 2016 No recent reports of development identified for research development in Ovarian-cancer in USA
- 16 Jul 2016 No recent reports of development identified for research development in Ovarian-cancer(Diagnosis) in USA